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Abstract 
Background: A variety of infections, including acute and recurrent urinary tract infections (UTIs), can trigger 
production of antiphospholipid antibodies (aPL).  These antibodies in women can lead to recurrent pregnancy loss. 
The aim of this study was to evaluate the prevalence of aPL in recurrent UTI patients.Materials and Methods: A 
total 52 subjects who had positive urine culture and 50 healthy individuals as controls were evaluated for presence of 
lupus anticoagulant (LA), anticardiolipin, anti-β2 GPI(anti-𝛽2-glycoprotein I) autoantibodies  IgM and IgG and 
Interleukin-8 levels. Determination of lupus anticoagulant was done by Activated Partial Thromboplastin Time 
(aPTT). Anticardiolipin and anti-β2 GPI autoantibodies were evaluated by ELISA method. Interleukin-8 values were 
also evaluated using ELISA method. Results: Escherichia coli (86.61%) and Proteus mirabilis (1.92%) had the 
highest and lowest frequency respectively. The prevalence of anti- β2 GPI IgG and IgM isotypes and 
anticardiolipin IgG and IgM isotypes or LA in UTI patients and healthy controls was 0.0%. There was significant 
association between neutrophil counts and IL-8 levels at the p < 0.01.Conclusion: Our results showed that in the 
UTI group and controls evaluated antiphospholipid antibodies were not present. The production of antiphospholipid 
antibodies is influenced by various genetic and environmental factors and chronic urinary tract infection alone is not 
the cause. This can affect the prevalence of antiphospholipid antibodies in various populations. However, other 
factors, such as the type of antiphospholipid antibody, sampling season and methodology can affect the results. 
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A combination of host genetic factors and 
exposure to environmental factors triggers the 
development of autoimmune diseases (1). Microbial 
agents or viruses, as environmental factors can 
induce autoimmune diseases by a variety of 
mechanisms such as polyclonal activation, 
unbalancing the immune response, their 
superantigens, release of cytokines and chemokines 
and molecular mimicry (1, 2). 
In the case of antiphospholipid syndrome 
(APS), anticardiolipin and anti-𝛽2 glycoprotein I 
pathogenic antibodies are detected. Although there is 
molecular mimicry between 𝛽2 GPI and infections, 
such as cytomegalovirus, haemophilus influenza, 
neisseria gonorrhoeae, rubella, toxoplasma and tetanus 
toxoid, and IgM antibodies against them have been 
detected, the direct connection between these 
infections and APS has not been established (1). The 
classical antiphospholipid syndrome is characterized 
by the presence of antiphospholipid antibodies (aPL) 
which bind target phospholipid molecules, mainly 
through β2 GPI, and are associated with recurrent fetal 
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loss and thromboembolic phenomena. Many 
infections are associated with increases in aPL. Skin 
infections (18%), human immunodeficiency virus 
(HIV) infection (17%), pneumonia (14%), hepatitis C 
virus (HCV) (13%), and urinary tract infections 
(10%) constituted the most common infections found 
as ‘‘triggering’’ factors (2,3).  
            Urinary tract infections (UTI) are one of the 
most common infections in women worldwide and 
Escherichia coli is the most prevalent causative 
organism of UTI and is solely responsible for more 
than 80% of these infections (4,5). Recent years, the 
understanding of the host-pathogen interaction and 
activation of the immune response in the urinary tract 
has increased considerably. Attachment to the 
uroepithelial cells by bacterial fimbriae allows for 
close contact between host and pathogen. 
Transmembrane signaling through TLRs leads to the 
production of inflammatory mediators such as 
chemokines with subsequent recruitment of 
professional immune cells to the infectious focus. 
Specifically, the CXC chemokine IL-8 is needed for 
neutrophil recruitment and activation in the urinary 
tract. The neutrophils may however also, cause 
unwanted effects for the host such as tissue 
destruction and autoantibody production (6).  
           Because women with recurrent urinary tract 
infection may produce aPL and are prone to recurrent 
miscarriage, the aim of this study was to evaluate the 
prevalence of aPL in recurrent UTI patients. 
 
Methods 
Patient selection. A total 52 subjects who had 
positive urine culture and 50 healthy individuals as 
controls were selected from the patients referred to 
Bu- Ali Polyclinic of Qom, Iran and enrolled in this 
study (Summer et al, 2015). Informed consent was 
obtained from all participants and approved by the 
ethical committee of the Qom University of Medical 
Sciences. Questionnaire consisting of a series of 
questions about age, history of infection, drug 
medication, miscarriages, and history of bruising, 
burning sensation, stroke, cardiovascular diseases, 
pregnancy, diabetes, systemic lupus erythematosus 
(SLE) and other autoimmune diseases were 
completed by all participants. Also participants were 
interviewed and examined by physician to determine 
characteristics and medical conditions. The complete 
history was taken and clinical assessment was done. 
All patients were nonsmokers, had no history of 
medical situations such as, chronic viral infections 
(e.g. HBV, HCV and HIV), Helicobacter pylori 
infection, Neisseria gonorrhoeae infection, recent non 
chronic infections (e.g. Streptococcal infections), 
diabetes mellitus, aspirin, heparin, warfarin or 
corticosteroid intake; chronic systemic disease 
including any autoimmune diseases, 
car¬diopulmonary diseases; history of surgery, chronic 
renal failure (creatinine clearance test <30 ml/min), a 
chronic liver diseases, connective tissue diseases, 
permanent urinary catheter, urinary tract stent, 
nephrostomy tube, urinary incontinence, neurogenic 
bladder, kidney malformations, kidney stones, 
gynecological problems, malignancy and pregnancy. 
So, patients did not have any problems except for 
urinary tract infections. 
Urine culture, bacterial colony count and 
identify types of bacteria. Patients with clinical 
symptoms of UTI referred to Bu- Ali Polyclinic of 
Qom, Iran, were investigated. Clean-Catch midstream 
urine of the patients was collected in a sterile tube (4-5 
ml) and immediately transported to the laboratory. 
Guidelines for proper specimen collection were given 
to all patients on a printed card (7). A measured 
amount of urine, using calibrated loop method was 
inoculated to nutrient agar medium (Merck, Germany) 
for colony count. Equal or more than 104 CFU/ml of a 
single potential pathogen interpreted as positive UTI 
and a result of 102-104 CFU/ml was repeated. A less 
than102 CFU/ml was interpreted as negative UTI (8). 
Urine specimens were cultured for isolation of the 
microbial agents of UTI on blood agar and Mac Conky 
agar media (Himedia, India & Merck, Germany). All 
the bacteria isolated from urine in this study were 
identified using conventional biochemical tests (7, 9, 
10). 
The criteria for recurrent urinary tract infection 
were three UTIs with three positive urine cultures 
during a 12-month period, or two infections during the 
previous 6 months (11-14). 
 
Autoantibodies evaluation  
 
Determination of lupus anticoagulant. We 
used a lupus-sensitive activated partial thromboplastin 
time. Standard aPTT was performed by incubating 0.1 
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ml of patients or controls plasma with 0.1 ml of 
aPTT (Thermo Fisher Scientific, USA) for 5 min at 
37°C, after which 0.1 ml of 25 mM CaCl2 was added 
and the clotting time recorded. Samples with aPTT 
values above the 35.2 seconds were regarded as 
positive. 
  Determination of anticardiolipin ,  anti-β2 
GPI autoantibodies  IgM and IgG. Serum levels of 
anticardiolipin IgM and IgG and anti-β2 GPI IgG and 
IgM levels antibodies were measured using 
EUROIMMUN Medizinsche Labordiagnostika GA 
(Germany). According to the manufacturer’s 
instructions, the cut-off values for positivity were 
≥12 IgG or IgM for anticardiolipin. Specimens with 
less than 12 PL-IgM-u/ml or12 PL-IgG-u/ml were 
considered negative. For anti-β2 GPI IgG and IgM 
the cut-off values were ≥20 RU/ml. Specimens with 
less than 20 RU/ml were considered negative. 
           Interleukin-8 assessment. Serum 
quantification of IL-8 was performed with ELISA 
using affimetrix eBiosciences, Austria, with a 
detection limit of 2.0 pg/mL.  
         WBC and platelet count. WBC and platelet 
count was performed by BC-5800 hematology 
analyzer (Mindray, China). 
        CRP assessment. Serum CRP was measured by 
immunoturbidimetric method (COBAS, Roche 
Diagnostics, Basel, Switzerland). 
       Statistical analysis. Data and statistical analysis 
was done using SPSS 16 software. The data were 
expressed as mean ± SD and proportions were 
expressed as percentage. Normality distribu¬tion of 
data was first determined by Kolmogorov–Smirnov 
test. Variables were compared with the independent 
t-test or Mann–Whitney U-test. Correlations were 
calculated by Pearson or Spearman. P-value of less 
than 0.05 was considered statistically significant for 
all tests. 
Results 
Minimum and maximum age of the UTI 
patients was 12 and 51 years respectively. All 
Patients had a history of 7 to 9 UTI in the last three 
years. The frequency and percentage of bacteria 
isolated from UTI patients are presented in Table1. 
Escherichia coli (86.61%) and Proteus mirabilis 
(1.92%) had the highest and lowest frequency 
respectively. 
 
Table1. The frequency and percentage of bacteria 
isolated from UTI patients. 
 Frequency % 










Proteus mirabilis 1 1.92 
Total 52 100 
 
The prevalence of anti- β2 GP1 IgG and IgM 
isotypes and anticardiolipin IgG and IgM isotypes or 
LA in UTI patients and healthy controls was 0.0% 
(Table 2). 
Table2. Demographic and immunological 
characteristics of the study and control groups 
Characteristics Patients(n=52) Controls(n=50) P value 
Age(years) 27.87±9.37 27.94±9.18 0.97 
Anti- β2 GP1 IgG 0(0.0) 0(0.0)  
Anti- β2 GP1 IgM 0(0.0) 0(0.0)  
LA(%) 0(0.0) 0(0.0)  
aCL- IgM(%) 0(0.0) 0(0.0)  
aCL- IgG(%) 0(0.0) 0(0.0)  
WBC(cells/mm3) 7421.15±1897.09 6344.00±1466.10 0.004 
IL-8( Pg/ml) 82.98±185.15 18.05±13.13 0.027 
Plt(/mm3) 210.11±48.70 208.44±54.85 0.89 
CRP( mg/L) 44.22±12.14 14.05±12.01 0.027 
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 There was significant association between 
WBC and IL-8 levels at the p < 0.01. There was no 
significant association between age and IL-8 levels in 
both patients and control groups. 
Thrombocytopenia(less than 150,000 platelets per 
microliter) was observed in 6 patients. None of the 





            Our results showed that in the UTI group and 
controls, the anti- β2 GPI IgG and IgM isotypes and 
anticardiolipin IgG and IgM isotypes or LA were not 
present. But, the increase in leukocytes numbers, 
CRP and IL-8 concentrations were observed in 
patients. Therefore, it can be assumed that infections 
alone cannot trigger production of pathogenic aPL 
antibodies. 
          However, it was postulated that infections may 
be a trigger factor for the induction of pathogenic 
aPL in certain predisposed individuals. In fact aPLs 
have been found not only in patients with 
autoimmune diseases like SLE, but also in patients 
with various infections (15, 16). Asherson and et al. 
reported the presence of antiphospholipid antibodies 
in infectious diseases such as AIDS, tuberculosis, 
measles, chickenpox, hepatitis and others. They 
reported that 35% of catastrophic APS cases were 
preceded by an infection, with urinary tract infections 
reported to occur in 6% of the cases (17). These data 
suggests that urinary tract infections in a small 
percentage of patients may cause aPL production and 
other infections may be more important. 
In the general population, 1% to 5% of people 
have positive aPL (18). Infection-associated aPL 
appear temporarily and disappear within 2 or 3 
months in most cases (19). 
It has recently been demonstrated that there is a 
seasonal influence on the prevalence of these 
antibodies in normal healthy populations, with a 
higher prevalence in the winter months than in the 
summer; the significance of these findings with 
respect to the etiology of this disorder and to 
thromboembolism is not yet known. Familial 
clustering of raised aPL antibody levels and HLA 
linkages indicate that the antibodies probably occur in 
genetically susceptible hosts in response to some 
antigenic challenge (20). Since sampling was 
conducted in the summer, our results can be attributed 
to it. 
            One of the clues linking cell death to the onset 
of autoimmunity is provided by autoantibodies that 
bind apoptotic cells and recognize surface epitopes 
that include complexes of anionic phospholipids, such 
as phosphatidylserine (PS) and β2 GPI( 21, 22). 
Presumably, infection may cause inflammation and is 
not initial factor for production of autoantibody in 
infected individuals. So, appropriate removal of the 
apoptotic cells prevents the production of pathogenic 
autoantibodies. 
Other potential environmental triggers of APS 
development include vaccination, drugs and certain 
malignancies. However, to date, there is no conclusive 
evidence linking vaccination to the development of 
APS (23, 24). In this study, patients and controls were 
not taking other drugs (such as: chlorpromazine, 
amoxicillin, phenytoin, chlorothiazide, propranolol, 
antiarrhythmic drugs, antihypertensive medications, 
quinine, alpha-interferon, or Infliximab) except 
antibiotics and oral contraceptives. This may be one of 
the reasons for our results. 
Various animal models and family and 
population studies have been used to highlight HLA 
associations with the occurrence of aPL and the 
development of thrombosis in aPL-positive patients. 
Thus, Major Histocompatibility Complex (MHC) 
genes may influence not only autoantibody production 
but also disease expression itself (25). Other genes 
outside the MHC region also contribute to both 
autoantibody production and disease expression in 
APS. A polymorphism in domain 5 of β2 GPI, valine 
instead of leucine at position 247, is found more 
frequently in patients with APS than matched controls 
and is associated with anti β 2GPI autoantibody 
production in susceptible patients (26-28). The study 
did not examine patients genetically and maybe our 
cases were not genetically predisposed to produce 
antiphosphplipid antibodies. 
The clinical importance of IgA anti-β2 GPI has 
increased in the last few years due to the utilization of 
kits useful to detect IgA anti- β2 GPI and the task 
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force in the 13th International Congress on 
Antiphospholipid Antibodies (2010, Galveston, TX, 
USA) recommended testing for the IgA anti-β2 GPI 
in cases negative for IgG and IgM and when APS is 
still suspected (29). In this study, IgA anti-β2 GPI 
was not measured. 
It has been proposed that aPL belong to the 
natural antibodies, because they share many 
properties with these B1 cell derived antibodies. A 
non-specific stimulus by pathogen associated 
patterns (PAMP) which can activate pattern 
recognition receptors, e.g., toll-like receptors (TLR) 
stimulates an increase over basal antibody production 
by B1 cells. Subsequently, antigen producing B1 cell 
clones are positively selected by exposure to their 
autoantigens (30). Natural antibodies are those 
normally present and are not masked if the antigen is 
not normally present, as in the case of ABO blood 
group antibodies and others, e.g. If the antigen is 
normally present, the natural autoantibody is 
suppressed, either by circulating as an immune 
complex or by antiidiotype antibodies (31). 
Another factor that influences results can be 
the method. It is well recognized that conflicting 
reports are common in the literature on aPL detected 
by ELISA methods. Methodological pitfalls in aPL 
testing by ELISA techniques (e.g. Plate plastic, 
source and handling of aPL, blocking, washing, 
dilution, heat inactivation, temperature, calcium, 
serum vs plasma) may affect our results (31). 
It seems that neutrophilia and high levels of 
interleukin-8 and CRP represents innate immune 
activation, and the production of pathologic 
antibodies requires the activation of acquired 
immunity and T cells (32). 
The most likely scenario is a complex 
interplay of a multitude of environmental factors in a 
genetically susceptible patient, which then induces 
autoantibody development and consequently typical 
disease manifestations (32). Another hypothesis is 
that the prevalence of antiphospholipid antibodies is 
low among our patients truly. 
Conclusion 
In summary, various factors contribute to the 
development and detection of pathological 
autoantibodies, and apparently chronic UTI alone is 
not sufficient to stimulate pathologic antibodies 
production. In the other hand, it seems that a number 
of positive cases have been eliminated due to the 
inappropriate methodology. 
It is recommended that antiphospholipid IgA 
class, two types of different ELISA kits and lastly, 
other antiphospholipid antibodies are examined. 
Conflicts of Interest 
The authors declare that there is no conflict of interest. 
Acknowledgment 
          This study was performed as part of Mr. Ali 
Reza Azad Master’s thesis project at the Department 
of Microbiology, Qom Branch, Islamic Azad 
University, Qom, Iran 
References 
 
1. Vojdani, A. A potential link between environmental triggers and 
autoimmunity. Autoimmune Dis. 2014; 2014: 437231 
 
2- Shoenfeld, Y., Blank, M., Lervra, R. et al, Infectious origin of 
antiphospholipid syndrome. Ann Rheum Dis. 2006; 65: 2–6. 
 
3-Cervera R, Asherson RA, Acevedo ML, Gomez- Puerta JA, 
Espinosa G, De La Red G, et al. Antiphospholipid syndrome 
associated with infections: clinical and microbiological 
characteristics of 100 patients. Ann Rheum Dis 2004;63:1312–17. 
 
4-Zargar M , Javadi A, Hosseini Z , Shakeri T. Tracking CTX-M 
gene in Escherichia coli isolates from urinary  tract infection in 
over fifty years women. Bull. Env Pharmacol Life Sci 2015 ;l 
4(7):167-171 
5-Avcin T, Toplak N. Antiphospholipid antibodies in response to 
infection. Curr Rheumatol Rep 2007;9:212-8.  
 
6-   Marchetti T, Cohen M, de Moerloose P; Obstetrical 
antiphospholipid syndrome: from the pathogenesis to the clinical 
and therapeutic implications. Clin Dev Immunol. 
2013;2013:159124.  
 
7-Forbes  BA. Sahm DF, Weissfeld AS. Bailey and Scott's 
Diagnostic microbiology, 12th edition, Mosby Elsevier, 2007; 842-
55 
 
8-Schneider PF,  Riley TV. Staphylococcus saprophyticus urinary 
tract infections: Epidemiological data from Western Australia. Eur 
J Epidemiol. 1996;  12: 51-4. 
Azad et al.                                                         Antiphospholipid Antibodies in Women with Recurrent Urinary Tract Infection  
 Archives of Medical Laboratory Sciences 
6 
 
9-Mandell GL,  Bennett  JE Dolin R. Principles  and practice of 
infectious diseases.Churchill Livingstone 2005; 881-882. 
 
10-Mac Faddin  JF. Biochemical tests for identification of 
medical bacteria. 3rd ed. Philadelphia: Lippincott Williams and 
Wilkins, 2000 
 
11. Mohsin R, Siddiqui KM. Recurrent urinary tract infections in 
females. J Pak Med Assoc 2010; 60:55– 9. 
 
12. Albert X, Huertas I, Pereiro I, Sanfelix J, Gosalbes V, Perrotta 
C. Antibiotics for preventing recurrent urinary tract infection in 
non-pregnant women. Cochrane Database Syst Rev 2004; 
3:CD001209. 
 
13. Gopal M, Northington G, Arya L. Clinical symptoms 
predictive of recurrent urinary tract infections. Am J Obstet 
Gynecol 2007; 197:74.e1–4. 
 
14. Foster RT Sr. Uncomplicated urinary tract infections in 
women. Obstet Gynecol Clin North Am 2008; 35:235–48. 
 
 
15. Cervera R, Asherson RA. Antiphospholipid syndrome 
associated with infections: clinical and microbiological 
characteristics. Immunobiology 2005; 210: 735-41. 
 
16. Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, 
antiphospholipid syndrome and infections. Autoimmun Rev 2008; 
7:  272-7. 
 
17. Asheron RA, Ervera R. Antiphospholipid antibodies and 
infection. Ann Rheum Dis. 2003;62: 388–93. 
18. Misita CP, Moll S. Antiphospholipid antibodies. Circulation 
2005;112:e39-44. 
 
19. Dalekos GN, Zachou K, Liaskos C. The antiphospholipid 
syndrome and infection. Curr Rheumatol Rep 2001;3: 277-85. 
 
20. Rand JH. Molecular pathogenesis of the antiphospholipid 
syndrome. Circ Res 2002; 90(1):29-37.  
 
21. Tincani A, Taraborelli M, Cattaneo R. Antiphospholipid 
antibodies and malignancies. Autoimmun Rev. 2010;9: 200–2. 
 
22. Becarevic M, Ignjatovic S and Majkic-Singh N. Apoptosis. 
Annexin A5 and Anti- Annexin A5 antibodies in the 
antiphospholipid syndrome. J Med Biochem. 2013; 32: 89 –95. 
 
23. Molina V, Shoenfeld Y. Infection, vaccines and other 
environmental triggers of autoimmunity. Autoimmunity. 2005;38: 
235–45. 
 
24. Martinuc Porobic J, Avcin T, Bozic B, et al. Anti-phospholipid 
antibodies following vaccination with recombinant hepatitis B 
vaccine. Clin Exp Immunol. 2005;142: 377–80. 
 
25. Sebastiani GD, Galeazzi M. Genetic aspects of the 
antiphospholipid syndrome: HLA associations, Chapter 6. In: 
Cervera R, Reverter JC, Khamashta M, editors. Antiphospholipid 
syndrome in systemic autoimmune diseases, Handbook of systemic 
autoimmune diseases, vol.10. Oxford: Elsevier BC; 2009. p. 81–9. 
 
26. Hirose N, Williams R, Alberts AR, et al. A role for the 
polymorphism at position 247 of the beta2-glycoprotein I gene in 
the generation of anti-beta2-glycoprotein I antibodies in the 
antiphospholipid syndrome. Arthritis Rheum. 1999;42:1655–61. 
 
27. Atsumi T, Tsutsumi A, Amengual O, et al. Correlation between 
beta2-glycoprotein I valine/ leucine247 polymorphism and anti-
beta2-glycoprotein I antibodies in patients with primary 
antiphospholipid syndrome. Rheumatology (Oxford). 1999;38:721–
3. 
 
28. Prieto GA, Cabral AR, Zapata-Zuniga M, et al. Valine/valine 
genotype at position 247 of the beta2-glycoprotein I gene in 
Mexican patients with primary antiphospholipid syndrome: 




29. Martínez-Flores JA, Serrano M, Morales JM, Serrano A. 
Antiphospholipid Syndrome and Kidney Involvement: New 
Insights. Antibodies. 2016; 5(3):17. 
 
30. Lackner  KJ, Müller-Calleja N. Antiphospholipid Antibodies: 
Their Origin and Development. Antibodies 2016; 5: 15 
 
31. Horstman LL, Jy W, Bidot CJ, Ahn YS, Kelley R E, Zivadinov 
R. et al. Antiphospholipid antibodies: Paradigm in transition. 
Journal of Neuroinflammation 2009; 6: 3. 
32. Rohan Willis, Emilio B Gonzalez. Pathogenetic mechanisms of 
antiphospholipid antibody production in antiphospholipid 
syndrome. World J Rheumatol. 2015; 5(2): 59-68 
 
 
